Biotech

All Articles

Biopharma Q2 VC hit highest degree since '22, while M&ampA decreased

.Equity capital backing in to biopharma rose to $9.2 billion across 215 sell the second one-fourth o...

Bicara, Zenas seek IPOs to drive late-phase properties toward market

.Bicara Therapeutics and Zenas Biopharma have actually given new catalyst to the IPO market with fil...

Genentech to shut cancer cells immunology research study team

.Genentech will definitely shut its cancer cells immunology analysis department, and unit mind and a...

Kezar drops sound tumor however to show its truly worth in phase 1 test

.Kezar Life Sciences is losing its dim stage 1 solid cyst medication as the biotech goes all-in on i...

Acelyrin drops izokibep, lays off 3rd of workers

.Despite izokibep maintaining its own newfound winning touch in the facility, Acelyrin is no longer ...

Rivus' phase 2 obesity-related cardiac arrest test attacks endpoint

.Rivus Pharmaceuticals has plumped up the customers of its fat-busting, muscle-sparing drug applican...

Ovid halts preclinical job, IV course after soticlestat fail

.Ovid Rehab already disclosed final month that it was trimming back its own head count as the provid...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston Port

.Eli Lilly has actually opened a $700 million R&ampD facility in the Boston Seaport, improving its R...

Boundless Biography creates 'moderate' discharges 5 months after $100M IPO

.Simply 5 months after protecting a $100 million IPO, Boundless Bio is presently giving up some staf...

Halda's $126M is going to accelerate 'hold and get rid of' tumor medications

.The initial stages of oncology R&ampD aren't except interesting brand new techniques, and Halda Reh...